Literature DB >> 12454706

Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.

W Y Au1, S K Ma, L P Chung, C S Chim, Y L Kwong.   

Abstract

We report two cases of secondary acute promyelocytic leukemia (APL). One patient presented with concurrent APL and missed abortion 1 year after etoposide-based chemotherapy for gestational trophoblastic disease. A prolonged complete remission was achieved with standard chemotherapy. An elderly man developed APL 1 year after alkylator-based chemotherapy for mantle cell lymphoma (MCL). A complete clinical and molecular remission was obtained with chemotherapy and all- trans retinoic acid, followed by arsenic consolidation. Concomitant molecular relapse of APL and MCL clones was detected at 1 year, both of which responded to oral arsenic therapy. High-dose epipodophyllin is a dose risk for secondary APL, but alkylating agents may also be implicated. For patients with a history of active malignancy and heavy previous chemotherapy exposure, the use of nontoxic arsenic therapy appeared to be effective and prudent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454706     DOI: 10.1007/s00277-002-0552-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

Review 1.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

2.  The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome.

Authors:  Izabela Błażewicz; Berenika Olszewska; Marta Stawczyk-Macieja; Maciej Jaśkiewicz; Roman J Nowicki; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2021-05-22       Impact factor: 1.837

3.  Frequency and Risk Factors for Secondary Malignancies in Patients with Mycosis Fungoides.

Authors:  Fatma Pelin Cengiz; Nazan Emiroğlu; Nahide Onsun
Journal:  Turk J Haematol       Date:  2017-08-23       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.